Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press28210.17650/1726-9776-2009-5-4-7-12LECTUREЛЕКЦИЯINTERMITTENT HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCERИНТЕРМИТТИРУЮЩАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫAlekseyevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruNyushkoK. M.НюшкоК. М.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncological Research InstituteМНИОИ им. П.А. Герцена30122009547120408201404082014https://oncourology.abvpress.ru/oncur/article/view/282

Intermittent hormone therapy (IHT) is an effective and safe hormonal method in patients with prostate cancer (PC), which is as efficacious as continuous hormone therapy. IHT substantially improves quality of life at a therapy-free interval and reduces the cost of the performed therapy. IHT  

Интермиттирующая гормональная терапия (ИГТ) является эффективным и безопасным методом гормонального воздействия у больных раком предстательной железы (РПЖ), эффективность которого не уступает постоянной гормональной терапии. Проведение ИГТ существенно улучшает качество жизни пациентов в период отсутствия терапии и снижает стоимость проводимого лечения. ИГТ может быть рекомендована при терапии больных РПЖ в различных клинических ситуациях, в том числе у пациентов с наличием отдаленных метастазов.

 

prostate cancertreatment policyintermittent hormone therapyрак предстательной железылечебная тактикаинтермиттирующая гормональная терапия1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.2. Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385—402.Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385—402.3. Bayar D.P. Studies on prostatic cancer and its treatment. NY: Lea and Febiger, 1977.Bayar D.P. Studies on prostatic cancer and its treatment. NY: Lea and Febiger, 1977.4. Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275—82.Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275—82.5. Sato N., Gleave M.E., Bruchovsky N. et al. Intermittent androgen suppression delays progression of androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 1996;58(2):139—46.Sato N., Gleave M.E., Bruchovsky N. et al. Intermittent androgen suppression delays progression of androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 1996;58(2):139—46.6. Goldenberg S.L., Bruchovsky N., Gleave M.E. et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45(5):839—44.Goldenberg S.L., Bruchovsky N., Gleave M.E. et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45(5):839—44.7. Klotz I.H., Herr H.W., Morse M.J. et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1996;58:2546—50.Klotz I.H., Herr H.W., Morse M.J. et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1996;58:2546—50.8. Goldenberg S.L., Akakura K., Bruchovsky N. et al. Effects of intermittent androgen suppression on androgen- dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71(9):2782—90.Goldenberg S.L., Akakura K., Bruchovsky N. et al. Effects of intermittent androgen suppression on androgen- dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71(9):2782—90.9. Pether M., Goldenberg S.L. Intermittent androgen suppression. BJU Int 2004;93(3):258—61.Pether M., Goldenberg S.L. Intermittent androgen suppression. BJU Int 2004;93(3):258—61.10. Prapotnich D., Cathelineau X., Rozet F. et al. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009 [Epub ahead of print].Prapotnich D., Cathelineau X., Rozet F. et al. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009 [Epub ahead of print].11. Opfermann K.J., Lai Z., Essenmacher L. et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer 2006;5(2):138—43.Opfermann K.J., Lai Z., Essenmacher L. et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer 2006;5(2):138—43.12. Pether M., Goldenberg S.L., Bhagirath K., Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003;10(2):1809—14.Pether M., Goldenberg S.L., Bhagirath K., Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003;10(2):1809—14.13. Lane T.M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117—22.Lane T.M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117—22.14. Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen depriva tion is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984—90.Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen depriva tion is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984—90.15. De Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total andro- gen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163—71.De Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total andro- gen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163—71.16. Salonen A.J., Viitanen J., Lundstedt S. et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: inter- im analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180(3):915—9.Salonen A.J., Viitanen J., Lundstedt S. et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: inter- im analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180(3):915—9.17. Tunn U.W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate can- cer. Eur Urol 1999;35 (Suppl 1): 27—31.Tunn U.W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate can- cer. Eur Urol 1999;35 (Suppl 1): 27—31.18. Kaneko Y., Maekawa S., Arakaki R. et al. Intermittent androgen deprivation therapy may prolong the duration of andro- gen dependence of well-differentiated prostate cancer. Hinyokika Kiyo 2006;52(4):259—64.Kaneko Y., Maekawa S., Arakaki R. et al. Intermittent androgen deprivation therapy may prolong the duration of andro- gen dependence of well-differentiated prostate cancer. Hinyokika Kiyo 2006;52(4):259—64.19. Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermit- tent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;1(25):18.Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermit- tent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;1(25):18.20. Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008;54(2): 382—91.Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008;54(2): 382—91.21. Calais da Silva F.E., Bono A.V., Whelan P. et al. Intermittent androgen dep- rivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55(6):1269—77. Epub 2009 Feb 21.Calais da Silva F.E., Bono A.V., Whelan P. et al. Intermittent androgen dep- rivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55(6):1269—77. Epub 2009 Feb 21.22. Алексеев Б.Я. Лечение локализованного и местнораспространенного рака предстательной железы. Автореф. дис. ... докт. мед. наук. М., 2006.Алексеев Б.Я. Лечение локализованного и местнораспространенного рака предстательной железы. Автореф. дис. ... докт. мед. наук. М., 2006.23. EAU Guidelines, 2009.EAU Guidelines, 2009.